Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Thrombopoietin Antibodies:
anti-Mouse (Murine) Thrombopoietin Antibodies:
anti-Rat (Rattus) Thrombopoietin Antibodies:
Go to our pre-filtered search.
Human Monoclonal Thrombopoietin Primary Antibody for FACS, ELISA - ABIN969571
Graziano, Carone, Panza, Marino, Magini, Romeo, Pession, Seri: Association of hereditary thrombocythemia and distal limb defects with a thrombopoietin gene mutation. in Blood 2009
Show all 2 Pubmed References
Dog (Canine) Polyclonal Thrombopoietin Primary Antibody for WB - ABIN2787808
Baker, Gray, Wright, Fitzsimons, Nimmo, Lowry, Mutrie,: The effect of a pedometer-based community walking intervention "Walking for Wellbeing in the West" on physical activity levels and health outcomes: a 12-week randomized controlled trial. in The international journal of behavioral nutrition and physical activity 2008
Show all 2 Pubmed References
Human Polyclonal Thrombopoietin Primary Antibody for IF (p), IHC (p) - ABIN1714401
Nakamura-Ishizu, Takubo, Kobayashi, Suzuki-Inoue, Suda: CLEC-2 in megakaryocytes is critical for maintenance of hematopoietic stem cells in the bone marrow. in The Journal of experimental medicine 2015
results confirm that TPO acts as an acute phase protein (show ORM1 Antibodies) but exclude the possibility that it is uniquely responsible for thrombocytosis of inflammatory disorders, which might recognize in IL-6 (show IL6 Antibodies) a credible candidate as a cooperating factor.
evidence for the presence of a low TPO gene expression transcript in B-CLL cells; early B-cell CLL circulating level of TPO does not provide a useful insight into the complex interrelationship of prognostic variables
Thrombopoietin levels are increased in patients with severe acute respiratory syndrome; TPO may have a role in thrombocytosis, which frequently develops from thrombocytopenia in SARS (show SARS Antibodies) patients
separate binding sites on the Mpl receptor for TPO and hNUDC identified
Tensin2 is an important new mediator in TPO/c-Mpl (show MPL Antibodies) pathway; Tensin2 becomes phosphorylated in a TPO dependent manner.
perioperative TPO dynamics are associated with postoperative LD. Postoperative TPO levels were found to be lowest in high-risk patients (HCC (show FAM126A Antibodies) patients undergoing major resection) but showed an independent predictive value.
Data indicate thrombopoietin (TPO) as potential early prognostic biomarker in acute pancreatitis (AP) patients.
These studies demonstrate that biallelic loss-of-function mutations in THPO cause bone marrow failure, which is unresponsive to transplant due to a hematopoietic cell-extrinsic mechanism.
Genetically engineered mesenchymal stromal cells produce IL-3 (show IL-3 Antibodies) and TPO to further improve human scaffold-based xenograft models
bone marrow megakaryocytes possess a complete mechanism to synthesize the ECM (show MMRN1 Antibodies) components, and that thrombopoietin is a pivotal regulator of this new function inducing transforming growth factor-b1 (TGF-beta1 (show TGFB1 Antibodies)) release and consequent activation of the downstream pathways, both in vitro and in vivo
Increased TPO expression in HSCs following IL-11 (show IL11 Antibodies) exposure could be mimicked or blocked by inhibiting or overexpressing miR (show MLXIP Antibodies)-204-5p, respectively... IL-11 (show IL11 Antibodies) promoted Hematopoietic stem cell engraftment in a mouse model of aplastic anemia an effect that was attenuated in cells overexpressing miR (show MLXIP Antibodies)-204-5p.
this study assessed the physiological source of thrombopoietin, a key cytokine required for maintaining hematopoietic stem cell .
TPO and its receptor Mpl (show MPL Antibodies) are dispensable for platelet survival in adult mice
Thrombopoietin-mediated phosphorylation of STAT5 (show STAT5A Antibodies) triggers its genome-wide relocation to STAT (show STAT1 Antibodies) consensus sites, resulting in loss of a uSTAT5 program that restrains megakaryocytic differentiation and activation of STAT5 (show STAT5A Antibodies)-driven gene expression.
Furthermore, although the contribution of the TPO treated graft to long-term hematological engraftment was reduced, the TPO treated and untreated grafts both contributed significantly to long-term chimerism in vivo.
TPO treatment also promoted the peripheral induction of Foxp3 (show FOXP3 Antibodies)(+) Tregs in conjunction with elevated circulating TGF-beta (show TGFB1 Antibodies) levels.
novel findings about aspects of TPO action on stem cells
Mpl (show MPL Antibodies) expression, but not Tpo, is fundamental in the development of JAK2V617F(+) myeloproliferative neoplasms
Thrombopoietin/MPL (show MPL Antibodies) signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 (show MECOM Antibodies) leukemia.
Megakaryocytes regulate cell cycle quiescence of hematopoietic stem cell through the production of thrombopoietin.
The results demonstrate the possible involvement of locally produced TPO (show TPO Antibodies)/c-MPL (show MPL Antibodies) system as a 'physiological filter' in bovine ovary where they may promote cell selection by inducing proliferation of viable cells and scavenging non-viable cells.
These studies indicate that the functional role of Tpo in the differentiation of thrombocytes from hematopoietic stem and progenitor cells is well conserved among vertebrate organisms, positing the zebrafish as an excellent model to investigate diseases caused by dysregulated erythro- and thrombo-poietic differentiation.
Megakaryocytopoiesis is the cellular development process that leads to platelet production. The protein encoded by this gene is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. This protein is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. Mutations in this gene are the cause of thrombocythemia 1. Alternate splicing results in multiple transcript variants of this gene.
, c-mpl ligand
, megakaryocyte colony-stimulating factor
, megakaryocyte growth and development factor
, megakaryocyte stimulating factor
, myeloproliferative leukemia virus oncogene ligand
, thrombopoietin nirs variant 1
, C-mpl ligand
, thrombopoietin (myeloproliferative leukemia virus oncogene ligand, megakaryocyte growth and development factor)